Q-omics provides the consensus-scored SUSD2 profile across patient tissues and cancer cell-line models. SUSD2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SUSD2 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, SUSD2 protein abundance shows 28,432 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, and LUAD as cancer lineages where SUSD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUSD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUSD2 survival associations across molecular data types. SUSD2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUSD2 RNA expression–survival associations across cancer types. High SUSD2 expression shows unfavorable associations in UVM, LGG, LUSC and OV, but favorable associations in KIRC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SUSD2 RNA expression.
This table summarizes SUSD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SUSD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUSD2 shows lower tumor expression in LUAD, KIRP, KICH and LUSC and higher tumor expression in HNSC and BRCA. The LUAD box plot shows higher SUSD2 RNA expression in normal versus tumor tissue (log2 FC = −4.900, t-test p < 0.001).
This table shows molecular features associated with SUSD2 in patient tissues and cancer cell lines. In patient samples, SUSD2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SUSD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
